International Stem Cell Corporation, Oceanside, CA 92056, USA.
Differentiation. 2011 Jun;81(5):292-8. doi: 10.1016/j.diff.2011.01.002. Epub 2011 Feb 8.
Human parthenogenetic stem cells (hpSC) hold great promise as a source of pluripotent stem cells for cell-based transplantation therapy due to their ethical method of derivation as well as the enhanced capacity for immunomatching with significant segments of the human population. We report here the directed differentiation of hpSC to produce enriched populations of definitive endoderm. Moreover, we find that treatment of undifferentiated hpSC by trichostatin A (TSA) before applying the directed differentiation protocol significantly increases the proportion of definitive endoderm cells in the final population. TSA-pretreated as well as non-TSA-treated hpSC undergoing differentiation toward definitive endoderm demonstrate a similar temporal sequence of gene expression to that which occurs in the course of definitive endoderm differentiation during vertebrate gastrulation and for differentiation of hESCs to definitive endoderm. Creation of the definitive endoderm lineages from hpSC represents the critical first step toward the development of hpSC-based cellular therapies for diseases of the liver or pancreas.
人孤雌生殖干细胞(hpSC)作为基于细胞的移植治疗的多能干细胞的来源具有很大的潜力,因为它们的衍生方法合乎伦理,并且与人类的很大一部分人群具有增强的免疫匹配能力。我们在此报告了 hpSC 的定向分化,以产生丰富的确定内胚层群体。此外,我们发现,在应用定向分化方案之前,用曲古抑菌素 A(TSA)处理未分化的 hpSC 可显著增加最终群体中确定内胚层细胞的比例。接受定向分化为确定内胚层的 TSA 预处理和未经 TSA 处理的 hpSC 均表现出与在脊椎动物原肠胚形成过程中确定内胚层分化以及 hESC 分化为确定内胚层过程中发生的基因表达相似的时间顺序。从 hpSC 中产生确定的内胚层谱系代表了朝着开发基于 hpSC 的肝脏或胰腺疾病细胞疗法迈出的关键的第一步。